Malin Corporation
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 41.0m | - | - | - | - | - | - |
% growth | 17 % | - | - | - | - | - | - |
EBITDA | 2.0m | 2.7m | 13.9m | (1.3m) | (3.0m) | (3.0m) | (3.0m) |
% EBITDA margin | 5 % | - | - | - | - | - | - |
Profit | 87.7m | 37.8m | 12.9m | - | - | - | - |
% profit margin | 214 % | - | - | - | - | - | - |
EV / revenue | 5.3x | - | - | - | - | - | - |
EV / EBITDA | 108.0x | 108.3x | 5.3x | -42.6x | -31.2x | -31.7x | -32.1x |
R&D budget | 6.6m | - | - | - | - | - | - |
R&D % of revenue | 16 % | - | - | - | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | €303m Valuation: €324m | IPO | |
Total Funding | - |
Recent News about Malin Corporation
EditMalin plc is a publicly listed company headquartered in Ireland, specializing in investing in highly innovative life sciences companies. The company focuses on sectors such as oncology, immunology, and genetic diseases, where advanced life science and healthcare technologies have the potential to deliver transformative treatments for patients. Malin's business model revolves around providing long-term capital and strategic support to its investee companies, enabling them to reach their full value potential. The company aims to generate significant returns for its shareholders while achieving transformative outcomes for patients. Malin serves a diverse range of clients, primarily in the life sciences and healthcare sectors, and operates within the global market. The company makes money through capital appreciation and returns on its investments in these high-potential life sciences companies. The senior leadership team at Malin brings extensive expertise in life sciences, finance, and venture capital, ensuring a dynamic and strategically aware approach to investment.
Keywords: life sciences, oncology, immunology, genetic diseases, transformative treatments, long-term capital, strategic support, shareholder value, innovative technologies, healthcare investments.